In Phase C, individuals will get ABBV-744 and oral navitoclax. In Section D, members will obtain ABBV-744 and ruxolitinib. Contributors will get treatment right until disorder progression or perhaps the participants are not able to tolerate the study drugs. For all stream cytometry experiments, ten,000 cells for every replicate were https://johnd443seo7.bloginder.com/profile